Almirall SA Ordinary shares (LBTSF) – PRNewswire
-
Almirall achieves Core Net Sales growth of 5.1% to 436.6 MM Euros in H1
-
Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance
-
Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
-
Almirall's Full-Year 2021 Results : Almirall delivers high end of the 2021 upgraded guidance with solid performance from growth drivers
-
Almirall delivers solid nine months 2021 results and tightens its upgraded guidance
-
Almirall U.S. Supports The Skin Cancer Foundation's Mobile Skin Cancer Screening Program
-
Almirall delivers robust H1 performance and increases full-year guidance
-
Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis
-
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
-
Almirall's solid core business Q1 performance boosted by Growth drivers momentum
-
Almirall's 2020 Full-Year Results
-
Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora® Cream for treatment of plaque psoriasis
-
Almirall announces Gianfranco Nazzi as new CEO
-
Almirall and Happify Health enter into strategic partnership to develop evidence-supported digital therapeutics solutions for psoriasis patients
-
Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies
-
Almirall announces collaborations with the University of South Australia and Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
-
Pablo Alvarez appointed to President and GM of Almirall US
-
Almirall demonstrates resilient performance year to date despite COVID-19 impacts
-
The Board of Directors nominates Carlos Gallardo as Vice President of the Board
-
Almirall and the University of Dundee announce a multi-target research collaboration to develop novel Targeted Protein Degraders medicines
-
Almirall: Sustained performance of key growth drivers and excellent progress on pipeline in H1 despite negative impact of COVID-19
Back to LBTSF Stock Lookup
